Scroll
down

HLA class I peptide polymorphisms contribute to class II DQβ0603:DQα0103 antibody specificity - Dr Cédric USUREAU #Club TIJC 6bis

WEBINAR Transdisciplinary Immunology Journal Club
HLA class I peptide polymorphisms contribute to class II DQβ0603:DQα0103 antibody specificity  
Cédric USUREAU
Wednesday, May 21, 2025 from 4:00 PM to 5:00 PM
REGISTRATION here >> to get the ZOOM link!

TIJC REPLAY

Revoir en Replay TIJC#7
Anti-PD-1 amplifies co-stimulation in melanoma-infiltrating Th1-like Foxp3+ Regulatory T cells to alleviate local immunosuppression  
Mikhaël ATTIAS 
Thursday, June 19, 2025 from 5:00 PM to 6:00 PM
TIJC 7 2025JuneVF


Revoir en Replay TIJC#6
Evolution of myeloid-mediated immunotherapy resistance in prostate cancer : Lyu A & al. Nature.2025  par le Dr Simon COIBA, disponible ICI

Revoir en Replay TIJC#7
Anti-PD-1 amplifies co-stimulation in melanoma-infiltrating Th1-like Foxp3+ Regulatory T cells to alleviate local immunosuppression  
Mikhaël ATTIAS
Thursday, June 19, 2025 from 5:00 PM to 6:00 PM
TIJC 7 2025JuneVF

Revoir en Replay TIJC#5
Neoantigen vaccines: a new era of precision medicine in oncology par le Dr Adrien MOUREN, disponible ICI

Revoir en Replay TIJC#4
Hallmarks of CD8+ T cell dysfunction are established within hours of tumor antigen encounter before cell division (Nat Immunol.) par le Dr Matthieu Roulleau Dugage, disponible ICI

Revoir en Replay TIJC#3
Targeting CD206+ macrophages disrupts the establishment of a key antitumor immune axis, JExpMed. 
With Dr Marie ROBERT. REPLAY HERE ! 

Revoir en Replay TIJC#2
The type 2 cytokine Fc–IL-4 revitalizes exhausted CD8+ T cells against cancer, Nature 2024. Par le Dr François-Xavier Danlos, disponible ICI

Revoir en Replay TIJC#1
JAK Inhibitors and Cancer: Friend or Foe? Par le Dr Samuel Bitoun, disponible ICI

Date
Wednesday, May 21, 2025
Time
From 4:00 PM to 5:00 PM
Place
online webinar